Insights & Resources

Rising physician compensation and growing financial losses are putting health systems under pressure. Explore the 2024 trends and valuation insights.

The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.

New York’s business interruption law introduced new stand-alone coverage opportunities, providing businesses options for tailored protection.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.

The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.

Ardent Health’s recent IPO highlights the company’s unique qualities, though it creates valuation comparability challenges for joint ventures and leased facilities.

The instances of urgent care clinic visits have returned to pre-pandemic levels, but COVID-related services still make up a large percentage of the total volume.

The home health and hospice sectors are facing significant challenges with personal care emerging as the key sector for mitigating risk.

High-growth specialties are influencing the fair market value of ambulatory surgery centers and setting new standards for premium valuations.

Discovery target lists can enhance asset recovery efforts in litigation and judgment enforcement by providing a strategic roadmap for enforcement and collections.

Explore Weaver's insights on the current health care deal volume decline and valuation.

By adopting best practices for fraud prevention and fostering a culture of transparency, NFPs can safeguard their resources and continue to make a positive impact.